Literature DB >> 22246374

How the immunoassay transformed C-peptide from a duckling into a swan.

J Roth1, I Whitford, R Dankner, A L Szulc.   

Abstract

This edition of 'Then and now' re-examines Lise Heding's very highly cited paper 'Radioimmunological determination of human C-peptide in serum', which was published in Diabetologia in 1975. We show how this article and other related articles by Heding contributed to heightened respect for C-peptide (and transformation of Heding's research programme). Initially thought of as an inert discard, C-peptide in blood is now recognised as an excellent surrogate measure of insulin secretion under a wide range of conditions. The assay is especially valuable for acute ascertainment of the insulin secretory capabilities of patients with type 1 diabetes or of transplanted beta cells. The assay is also being used to monitor endogenous beta cell loss or in vivo expansion of beta cell mass over the long term. We conclude with two promising future applications: (1) measurements of C-peptide in blood (along with insulin, glucose, and HbA(1c)) at annual intervals as a potential approach to earlier diagnosis of diabetes; and (2) among many recent advances in recognising properties of C-peptide (including status as a candidate hormone), most promising is C-peptide as a possible therapy for diabetic neuropathy and nephropathy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22246374     DOI: 10.1007/s00125-011-2421-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  21 in total

1.  Immunoassay of endogenous plasma insulin in man.

Authors:  R S YALOW; S A BERSON
Journal:  J Clin Invest       Date:  1960-07       Impact factor: 14.808

Review 2.  C-peptide and long-term complications of diabetes.

Authors:  Patrizia Luppi; Vincenza Cifarelli; John Wahren
Journal:  Pediatr Diabetes       Date:  2010-12-05       Impact factor: 4.866

3.  The biosynthesis of insulin and a probable precursor of insulin by a human islet cell adenoma.

Authors:  D F Steiner; P E Oyer
Journal:  Proc Natl Acad Sci U S A       Date:  1967-02       Impact factor: 11.205

4.  C-peptide is a bioactive peptide.

Authors:  J Wahren; K Ekberg; H Jörnvall
Journal:  Diabetologia       Date:  2007-01-18       Impact factor: 10.122

5.  Lise G. Heding, 1936-2008.

Authors:  J Ludvigsson
Journal:  Diabetologia       Date:  2009-10       Impact factor: 10.122

6.  A tribute to Rosalyn S. Yalow.

Authors:  Jesse Roth
Journal:  J Clin Invest       Date:  2011-07-01       Impact factor: 14.808

7.  Radioimmunological determination of human C-peptide in serum.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1975-12       Impact factor: 10.122

8.  Adventures with insulin in the islets of Langerhans.

Authors:  Donald F Steiner
Journal:  J Biol Chem       Date:  2011-03-28       Impact factor: 5.157

9.  C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat.

Authors:  A A Sima; W Zhang; K Sugimoto; D Henry; Z Li; J Wahren; G Grunberger
Journal:  Diabetologia       Date:  2001-07       Impact factor: 10.122

Review 10.  The proinsulin C-peptide--a multirole model.

Authors:  Donald F Steiner
Journal:  Exp Diabesity Res       Date:  2004 Jan-Mar
View more
  3 in total

1.  C-peptide preserves the renal microvascular architecture in the streptozotocin-induced diabetic rat.

Authors:  Elizabeth R Flynn; Jonathan Lee; Zachary M Hutchens; Alejandro R Chade; Christine Maric-Bilkan
Journal:  J Diabetes Complications       Date:  2013-08-29       Impact factor: 2.852

Review 2.  C-Peptide replacement therapy in type 1 diabetes: are we in the trough of disillusionment?

Authors:  C W Pinger; K E Entwistle; T M Bell; Y Liu; D M Spence
Journal:  Mol Biosyst       Date:  2017-07-25

3.  Autoimmune diabetes is suppressed by treatment with recombinant human tissue Kallikrein-1.

Authors:  Lilia Maneva-Radicheva; Christina Amatya; Camille Parker; Jacob Ellefson; Ilian Radichev; Arvind Raghavan; Matthew L Charles; Mark S Williams; Mark S Robbins; Alexei Y Savinov
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.